Sam Brusco, Associate Editor01.28.22
Insulet has received U.S. Food and Drug Administration (FDA) clearance for its Omnipod 5 automated insulin delivery system for those with type 1 diabetes aged six and older. The tubeless automated insulin delivery (AID) system integrates with the Dexcom G6 continuous glucose monitoring (CGM) system,
Omnipod 5 requires no multiple daily injections, no tubes, and no fingersticks to help manage diabetes.
“Omnipod 5 is a life-changing technology that we believe will revolutionize the market and the lives of people with diabetes,” said Shacey Petrovic, president and CEO of Insulet told the press. “We are incredibly proud of this simple-to-use, elegant system, designed to deliver unmatched freedom and to greatly simplify insulin management and improve glucose control for our users.”
The system is comprised of the tubeless pod with SmartAdjust technology, the Dexcom G6 CGM, and a mobile app with a SmartBolus Calculator. This app can be downloaded onto a compatible smartphone, or the Omnipod 5 Controller can be used.
The SmartAdjust tool receives a Dexcom CGM value every five minutes and predicts glucose level an hour into the future. The insulin delivery is then increased, decreased, or paused using desired and customized insulin target.
“As the pioneer of integrated CGM, we are excited to see our years of collaborative work with Insulet culminate into the first and only FDA-cleared tubeless automated insulin delivery system,” said Kevin Sayer, Chairman, president, and CEO of Dexcom. “Omnipod 5 combines the accuracy and unmatched user experience of the Dexcom G6 CGM with the simplicity of tubeless insulin delivery to offer people with diabetes a revolutionary new way to optimize time in range.”
Omnipod 5 will launch through the pharmacy channel. It will be launched in a limited market release in the coming days, and become broadly available shortly after that.
Omnipod 5 requires no multiple daily injections, no tubes, and no fingersticks to help manage diabetes.
“Omnipod 5 is a life-changing technology that we believe will revolutionize the market and the lives of people with diabetes,” said Shacey Petrovic, president and CEO of Insulet told the press. “We are incredibly proud of this simple-to-use, elegant system, designed to deliver unmatched freedom and to greatly simplify insulin management and improve glucose control for our users.”
The system is comprised of the tubeless pod with SmartAdjust technology, the Dexcom G6 CGM, and a mobile app with a SmartBolus Calculator. This app can be downloaded onto a compatible smartphone, or the Omnipod 5 Controller can be used.
The SmartAdjust tool receives a Dexcom CGM value every five minutes and predicts glucose level an hour into the future. The insulin delivery is then increased, decreased, or paused using desired and customized insulin target.
“As the pioneer of integrated CGM, we are excited to see our years of collaborative work with Insulet culminate into the first and only FDA-cleared tubeless automated insulin delivery system,” said Kevin Sayer, Chairman, president, and CEO of Dexcom. “Omnipod 5 combines the accuracy and unmatched user experience of the Dexcom G6 CGM with the simplicity of tubeless insulin delivery to offer people with diabetes a revolutionary new way to optimize time in range.”
Omnipod 5 will launch through the pharmacy channel. It will be launched in a limited market release in the coming days, and become broadly available shortly after that.